CAR-T Cell Therapies Show Promise for Autoimmune Disease at ACR Convergence 2025

CHICAGO – Two pioneering studies presented at ACR Convergence 2025 spotlight the potential of CAR-T cell therapies to transform treatment for systemic lupus erythematosus (SLE) and other autoimmune diseases. These early findings suggest a new frontier in immune modulation and long-term disease remission.

Dual-Targeted CAR-T Therapy for Lupus
Abstract #2129706
Researchers unveiled preliminary results from a study of CTA313, a dual-targeted CAR-T therapy designed to attack both CD19 and BCMA. In patients with active SLE, the therapy demonstrated encouraging safety, efficacy, and cellular kinetics. By targeting both B cells and plasma cells, CTA313 may offer a novel therapeutic option for individuals with refractory lupus.

CD19 CAR-T Therapy Across Autoimmune Conditions
Abstract #2129320
Another study explored CTA311, a CD19-targeted CAR-T therapy, in patients with active autoimmune diseases. The data revealed promising early outcomes, highlighting CAR-T’s potential to recalibrate immune responses and induce durable remission across a spectrum of autoimmune disorders.

Together, these studies underscore a growing momentum in autoimmune research—one that embraces cellular therapies and precision immunology to improve outcomes for patients facing chronic, complex conditions.

Media Contact
Teri Arnold
Director, Public Relations & Communications
tarnold@rheumatology.org
757-272-7002

###

About the American College of Rheumatology
Founded in 1934, the American College of Rheumatology (ACR) is a not-for-profit, professional association committed to advancing the specialty of rheumatology that serves over 10,000 physicians, health professionals, researchers and scientists worldwide. In doing so, the ACR offers education, research, advocacy and practice management support to help its members continue their innovative work and provide quality patient care. Rheumatology professionals are experts in the diagnosis, management and treatment of more than 100 different types of arthritis and rheumatic diseases.

About ACR Convergence
ACR Convergence, the annual meeting of the American College of Rheumatology, is where rheumatology meets to collaborate, celebrate, congregate, and learn. With hundreds of sessions and thousands of abstracts, it offers a superior combination of basic science, clinical science, business education and interactive discussions to improve patient care and advance the specialty. For more information about the meeting, visit the ACR Convergence page, or join the conversation on X by following the official hashtag (#ACR25).